Experimental Hematology & Oncology最新文献

筛选
英文 中文
CAR immunotherapy for cancer: from ex vivo manufacturing to in vivo immune cell engineering. CAR免疫治疗癌症:从体外制造到体内免疫细胞工程。
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-11-12 DOI: 10.1186/s40164-026-00858-1
Ziqiang Liu, Dezheng Kong, Pengwu Liang, Zhengze Li, Tingting Tan, Xin Dong, Ruizhen Li, Lifeng Li, Yi Zhang, Guozhu Xie
{"title":"CAR immunotherapy for cancer: from ex vivo manufacturing to in vivo immune cell engineering.","authors":"Ziqiang Liu, Dezheng Kong, Pengwu Liang, Zhengze Li, Tingting Tan, Xin Dong, Ruizhen Li, Lifeng Li, Yi Zhang, Guozhu Xie","doi":"10.1186/s40164-026-00858-1","DOIUrl":"https://doi.org/10.1186/s40164-026-00858-1","url":null,"abstract":"<p><p>Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has achieved durable remissions in patients with relapsed or refractory haematological malignancies. However, its broader clinical adoption remains constrained by patient-specific ex vivo manufacturing, substantial treatment-related toxicities and limited efficacy in solid tumours. In vivo CAR immunotherapy enables endogenous immune cells to be genetically reprogrammed directly within the body, bypassing leukapheresis, ex vivo expansion and individualized cell manufacturing. This Review focuses specifically on in vivo CAR immune cell engineering for cancer therapy, encompassing haematological malignancies and solid tumours; applications in non-malignant diseases, including autoimmune disorders, are outside its scope. We examine emerging technologies for generating CAR immune cells in vivo and discuss how viral vectors, non-viral nanocarriers and biomimetic delivery systems could improve the precision, scalability and controllability of cancer immunotherapy. We further highlight immune effectors beyond CAR T cells, including CAR macrophages and CAR natural killer cells, whose distinct cytotoxic, phagocytic and immunomodulatory functions may offer complementary approaches to treating solid tumours. We discuss strategies involving tumour-microenvironment remodelling, metabolic adaptation and precision genome engineering to improve immune-cell persistence, mitigate functional exhaustion, enhance tumour infiltration and limit antigen escape. Emerging clinical studies in haematological malignancies provide initial proof of concept that functional CAR cells can be generated in patients, although long-term safety, durability and reproducibility remain to be established. A central challenge is to generate these cells with sufficient cellular and spatial precision while maintaining control over their activity over time. We discuss how cell-subset-specific delivery, programmable CAR circuits, multicellular engineering, intelligent biomaterials and artificial intelligence could support the development of in vivo CAR immunotherapy as a scalable, controllable and potentially repeatable cancer treatment.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13760852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149403595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RBP1-driven retinol metabolism in tumor-associated lymphatic endothelial cells orchestrates triple-negative breast cancer progression and lymphatic metastasis. 肿瘤相关淋巴内皮细胞中rbp1驱动的视黄醇代谢协调三阴性乳腺癌的进展和淋巴转移。
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-11-12 DOI: 10.1186/s40164-026-00842-9
Nieves Montenegro-Navarro, Estefanía Díaz Del Cerro, Carmen Jordán-Pérez, Enrique de Álava, Melissa García-Caballero
{"title":"RBP1-driven retinol metabolism in tumor-associated lymphatic endothelial cells orchestrates triple-negative breast cancer progression and lymphatic metastasis.","authors":"Nieves Montenegro-Navarro, Estefanía Díaz Del Cerro, Carmen Jordán-Pérez, Enrique de Álava, Melissa García-Caballero","doi":"10.1186/s40164-026-00842-9","DOIUrl":"https://doi.org/10.1186/s40164-026-00842-9","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and is characterized by a high metastatic potential and limited treatment options. TNBC frequently metastasizes to lymphatic vessels and the presence of breast cancer cells in tumor-draining lymph nodes (LNs) is an important prognostic factor. Nevertheless, the molecular and metabolic reprogramming of TNBC-associated lymphatic vasculature remains poorly understood.</p><p><strong>Methods: </strong>A comprehensive single-cell RNA sequencing analysis of 44,000 endothelial cells from human breast tumor datasets was performed. RBP1, a retinol-binding protein, was identified as a metabolic gene highly and specifically upregulated in tumor-associated lymphatic endothelial cells (LECs). Then, RBP1 expression in human TNBC biopsies was assessed, and its association with LN status and overall patient survival was investigated in a cohort of 1,474 breast cancer patients. We further evaluated the in vivo relevance of RBP1 by CRISPR/Cas9-mediated Rbp1 knockout in a pre-clinical TNBC mouse model. In vitro functional studies were performed using co-culture systems and RBP1-silencing in LECs. Finally, RBP1 mechanism of action in the lymphatic vasculature was determined by bulk-RNA sequencing and validated by applying different cellular and molecular approaches.</p><p><strong>Results: </strong>Single-cell profiling revealed that the metabolic gene RBP1 was upregulated in LECs within the human breast tumor microenvironment. Further analysis showed that lymphatic RBP1 expression was associated with LN metastases, and correlated with poor prognosis and reduced survival in TNBC patients. In the pre-clinical TNBC mouse model, CRISPR-Cas9-mediated Rbp1 knockout reduced lymphangiogenesis, tumor growth and metastatic burden, and increased necrosis. Moreover, functional assays demonstrated that direct co-culture of LECs with TNBC cells, or exposure to their secretome, induced lymphatic RBP1 upregulation and enhanced pro-lymphangiogenic activities, whereas RBP1 silencing compromised their biological, redox and metabolic properties. Mechanistically, bulk RNA sequencing of RBP1-silenced LECs combined with experimental validation revealed that RBP1, through its retinol-binding domain, modulates the VEGFR3 and NOTCH pathways, while also involving lipid mobilization.</p><p><strong>Conclusions: </strong>We define lymphatic RBP1 as a key \"switch\" that couples LEC metabolism to molecular programs, thereby driving tumor-associated lymphangiogenesis, breast tumor growth and lymphatic dissemination in TNBC. Our findings underscore the potential of RBP1 as both a novel prognostic biomarker and a tractable therapeutic target for blocking TNBC progression and lymphatic metastasis.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149403596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A non-IMiD multi-target degrader reactivates fetal hemoglobin. 一种非imid多靶点降解剂可重新激活胎儿血红蛋白。
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-11-11 DOI: 10.1186/s40164-026-00846-5
Jun Liu, Ziyang Shen, Shin-Young Park, Yanhua Dong, Na Yu, Jing Zeng, Hannah Lee, Braden Pate, Sophia Adamia, Kim Vanuytsel, Junyan Zhang, Shang-Chuen Wu, Adelaide Herman, Shiva Moein, Wenhui Li, Miao Liu, Chong Gao, Xi Tian, Zhaoji Liu, Junsu Kwon, Kunhua Qin, Christoph Budjan, Claire Shao, Jiajia Li, Ernie Lee, Sanjana Arji, Bee-Hui Liu, Sean Stowell, John P Manis, David Justus, Gerd A Blobel, Hongbo R Luo, Roger Belizaire, Yi Zheng, Sahand Hormoz, Mahmoud A Bassal, Sarah Nikiforow, Jose A Cancelas, Daniel E Bauer, Daniel G Tenen, Li Chai
{"title":"A non-IMiD multi-target degrader reactivates fetal hemoglobin.","authors":"Jun Liu, Ziyang Shen, Shin-Young Park, Yanhua Dong, Na Yu, Jing Zeng, Hannah Lee, Braden Pate, Sophia Adamia, Kim Vanuytsel, Junyan Zhang, Shang-Chuen Wu, Adelaide Herman, Shiva Moein, Wenhui Li, Miao Liu, Chong Gao, Xi Tian, Zhaoji Liu, Junsu Kwon, Kunhua Qin, Christoph Budjan, Claire Shao, Jiajia Li, Ernie Lee, Sanjana Arji, Bee-Hui Liu, Sean Stowell, John P Manis, David Justus, Gerd A Blobel, Hongbo R Luo, Roger Belizaire, Yi Zheng, Sahand Hormoz, Mahmoud A Bassal, Sarah Nikiforow, Jose A Cancelas, Daniel E Bauer, Daniel G Tenen, Li Chai","doi":"10.1186/s40164-026-00846-5","DOIUrl":"10.1186/s40164-026-00846-5","url":null,"abstract":"<p><p>Reactivation of fetal hemoglobin (HbF) is a validated therapeutic strategy for sickle cell disease (SCD) and β-thalassemia. Cereblon (CRBN)-dependent molecular-glue degraders of HbF repressors are advancing clinically, but all share an immunomodulatory imide drug (IMiD) backbone and its class liabilities. We show that SH6, a non-IMiD small-molecule degrader, consistently induces HbF in erythroid cell lines, primary healthy-donor, SCD, and β-thalassemia CD34⁺-derived erythroid cells, and humanized NBSGW mice, at nanomolar to low-micromolar concentrations. When all compounds were tested at a matched 0.25µM concentration, HbF induction by SH6 was comparable to that of decitabine and greater than that of hydroxyurea, pomalidomide or thalidomide. HbF induction is CRBN/proteasome-dependent and associated with simultaneous degradation of the γ-globin repressors ZBTB7A and BCL11A. These findings provide proof of concept for IMiD-independent pharmacologic HbF reactivation and support further study of SH6 as a mechanistically distinct tool compound.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13753412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinct asciminib sensitivity profiles between BCR::ABL1 p190 and p210 isoforms. BCR::ABL1 p190和p210亚型之间不同的阿西米尼敏感性谱
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-11-11 DOI: 10.1186/s40164-026-00859-0
Elias Lagonik, Luke J Quinlan, Elyse C Page, Daniel P McDougal, Laura N Eadie, John B Bruning, David T Yeung, Timothy P Hughes, Deborah L White
{"title":"Distinct asciminib sensitivity profiles between BCR::ABL1 p190 and p210 isoforms.","authors":"Elias Lagonik, Luke J Quinlan, Elyse C Page, Daniel P McDougal, Laura N Eadie, John B Bruning, David T Yeung, Timothy P Hughes, Deborah L White","doi":"10.1186/s40164-026-00859-0","DOIUrl":"10.1186/s40164-026-00859-0","url":null,"abstract":"<p><p>BCR::ABL1 is the oncogenic driver of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph + ) acute lymphoblastic leukemia (ALL), with BCR::ABL1 p210 and p190 being the predominant isoforms. Asciminib, an inhibitor that specifically targets the ABL myristate pocket (STAMP), has demonstrated efficacy in both pre-clinical and clinical studies against p210-driven CML, including cases where resistance mediated by ATP-pocket mutations has developed during prior tyrosine kinase inhibitor (TKI) therapy. The resistant mutation profile of asciminib is currently considered largely distinct from that of ATP-competitive TKIs. In our study, we demonstrate that several ATP-pocket mutations, including the V299L, F311I, T315I, and F317C/L, confer high levels of resistance to asciminib in the p190 isoform (> 1000-fold increase in LD<sub>50</sub><sup>asciminib</sup> values compared to non-mutated BCR::ABL1 p190), but remain sensitive when occurring in the p210 isoform. The T315A was the only tested mutation in BCR::ABL1 p190 sensitive to asciminib. Furthermore, cells expressing BCR::ABL1 p190 mutations exhibited decreased kinase inhibition following STAMP treatment, indicative of an active kinase. Analogous results were obtained for MK-4208 (formerly known as TERN-701), a clinically active investigational STAMP compound. In the BCR::ABL1 p190 setting, this work reveals an overlapping resistance profile between STAMP compounds and TKIs, with important considerations for STAMP-based therapy. It challenges two key assumptions: that asciminib dose escalation can overcome resistant ATP-pocket mutations and that targeted therapy sensitivity profiles are equivalent between the p190 and p210 isoforms.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13753438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subtype-resolved tumor-intrinsic programs in immune-cold breast cancer: mechanistic interactions, evidence gaps, and translational priorities. 免疫冷性乳腺癌的亚型解决肿瘤内在程序:机制相互作用,证据差距和翻译优先权。
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-11-11 DOI: 10.1186/s40164-026-00853-6
Hung-Yu Lin, Shin-Mae Wang, Pei-Yi Chu
{"title":"Subtype-resolved tumor-intrinsic programs in immune-cold breast cancer: mechanistic interactions, evidence gaps, and translational priorities.","authors":"Hung-Yu Lin, Shin-Mae Wang, Pei-Yi Chu","doi":"10.1186/s40164-026-00853-6","DOIUrl":"10.1186/s40164-026-00853-6","url":null,"abstract":"<p><p>Most breast cancers respond poorly to immune checkpoint blockade (ICB), and hormone receptor-positive (HR +) tumors, which constitute most diagnoses, are particularly refractory. This review synthesizes evidence on tumor-intrinsic determinants of the immune-cold phenotype in breast cancer under an operational framework designated ICE, comprising three functionally defined domains: Invisibility (failure of antigen generation, presentation, and innate sensing), Coercion (active exclusion and post-infiltration suppression of effector cells), and Exhaustion-by-Metabolism (metabolic attrition of infiltrating lymphocytes). ICE is not proposed as a newly discovered taxonomy of immune evasion; its added value lies in integrating breast-cancer subtype resolution, evidence provenance, systems-level interactions, negative clinical evidence, and mechanism-biomarker-intervention matching within a single operational framework. Four features define this framework. The domains are overlapping rather than sequential, and an explicit assignment rule places multifunctional regulators such as MYC, hypoxia-inducible factor 1α, and lactate in a primary domain while cataloguing secondary effects. Tumor-immune interaction is treated as bidirectional, positioning tumor-intrinsic programs as both causes and consequences of immune pressure. Major mechanistic and translational claims are assigned claim-specific evidence tiers. Resistance to immune-mediated killing, including death receptor loss, is classified as cross-dimensional cytoprotection rather than a recognition defect. Applying this discipline exposes an asymmetric evidence base: antigen presentation defects and metabolic suppression rest on substantial preclinical data with limited clinical validation, several widely cited mechanisms derive from non-breast models, and the translational record includes cross-cancer constraints-failure of IDO1 inhibition in a melanoma phase III trial and minimal STING-agonist monotherapy activity in early mixed-solid-tumor studies-together with breast-cancer-specific negative findings from IMpassion131 and the unfavorable benefit-risk profile of abemaciclib plus pembrolizumab. Cross-dimensional systems-level structures, including the hypoxia-adenylosuccinate lyase-fumarate-STING axis and the tumor-macrophage arginine-polyamine relay, are identified as the most instructive examples of domain interaction, and seven falsifiable predictions are advanced, each specifying a measurable biomarker and a decisive experiment.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13753161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dismantling the immune-metabolic barrier in TP53-mutant hematologic malignancies. 拆除tp53突变血液病恶性肿瘤的免疫代谢屏障。
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-11-11 DOI: 10.1186/s40164-026-00857-2
Jingchao Su, Yifei Zeng, Yinglu Liu, Shiyi Liu, Kaixin Ou, Bolin Peng, Shuang Li, Yuhua Li, Sanfang Tu
{"title":"Dismantling the immune-metabolic barrier in TP53-mutant hematologic malignancies.","authors":"Jingchao Su, Yifei Zeng, Yinglu Liu, Shiyi Liu, Kaixin Ou, Bolin Peng, Shuang Li, Yuhua Li, Sanfang Tu","doi":"10.1186/s40164-026-00857-2","DOIUrl":"10.1186/s40164-026-00857-2","url":null,"abstract":"<p><p>Tumor protein 53 (TP53) mutations, long recognized as harbingers of poor prognosis, drive treatment failure in hematologic malignancies by erecting two mutually reinforcing defense systems. Immune evasion is effected through silencing of death-receptor signaling, crippled antigen presentation, and establishment of a T-cell-exclusionary microenvironment, while a parallel metabolic shield fortifies cells against oxidative, proteotoxic, and replicative stress. Here, we propose that immune evasion and metabolic fortification do not operate in complete isolation, but rather as an integrated defense network with emergent crosstalk nodes. We dissect how the spectrum of TP53 mutations dictates the configuration of this barrier, analyze why mono-modal therapies, from chimeric antigen receptor (CAR)-T cells and bispecific antibodies to chemotherapy and BCL-2 homology 3 (BH3) mimetics, have shown limited efficacy to date, and outline a roadmap for rationally designed, multi-node therapeutic combinations that may convert these integrated defenses into selective vulnerabilities. This synthesis offers a conceptual framework that may serve as both a mechanistic compass and a translational guide for tackling the high-risk genotypes in leukemia, lymphoma, and myelodysplastic syndromes (MDS).</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13753141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined casein kinase II and MAPK signalling inhibition as a therapeutic strategy for metastatic colorectal cancer. 酪蛋白激酶II和MAPK信号联合抑制作为转移性结直肠癌的治疗策略。
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-11-05 DOI: 10.1186/s40164-026-00855-4
Mattia Marinucci, Federico Donà, Gina F Boot, Cinzia Esposito, Elenia Toccafondi, Daniela Liberati, Andrej Benjak, Lara Zaidi, Melania Lazzari, Giulia Milardi, Karolina Guja-Jarosz, Miriam Cieri, Huiche Feng, Mairene Coto-Llerena, Raoul A Droeser, Savas D Soysal, Otto Kollmar, Guido Torzilli, Antonino Spinelli, Luigi M Terracciano, Charlotte K Y Ng, Salvatore Piscuoglio
{"title":"Combined casein kinase II and MAPK signalling inhibition as a therapeutic strategy for metastatic colorectal cancer.","authors":"Mattia Marinucci, Federico Donà, Gina F Boot, Cinzia Esposito, Elenia Toccafondi, Daniela Liberati, Andrej Benjak, Lara Zaidi, Melania Lazzari, Giulia Milardi, Karolina Guja-Jarosz, Miriam Cieri, Huiche Feng, Mairene Coto-Llerena, Raoul A Droeser, Savas D Soysal, Otto Kollmar, Guido Torzilli, Antonino Spinelli, Luigi M Terracciano, Charlotte K Y Ng, Salvatore Piscuoglio","doi":"10.1186/s40164-026-00855-4","DOIUrl":"10.1186/s40164-026-00855-4","url":null,"abstract":"<p><strong>Background: </strong>Metastatic colorectal cancer (mCRC) remains a significant clinical challenge due to the emergence of drug resistance, highlighting the need for new therapeutic strategies. Aberrant regulation of the proteome drives cancer progression, and dissecting these alterations offers opportunities for targeted intervention. We aimed to identify candidate kinase dependencies in mCRC and to test a rational combination strategy in patient-derived models.</p><p><strong>Methods: </strong>We performed proteomic and phosphoproteomic profiling of 10 mCRC tissues, their matched patient-derived organoids (PDOs) and normal colon mucosa, integrated with whole-exome sequencing. Kinase activities were inferred by kinase-substrate enrichment analysis. Silmitasertib-mediated casein kinase II (CKII) inhibition, alone and combined with the MEK inhibitor trametinib, was evaluated by ex vivo drug screening, western blot, flow cytometry and drug-interaction analysis across the PDO cohort and in normal colon PDOs.</p><p><strong>Results: </strong>PDOs recapitulated the molecular features of matched tumours. Both tissues and PDOs showed consistently elevated CKII activity. Silmitasertib exerted heterogeneous antitumour activity, and resistance was associated with MAPK and Akt-mTOR signalling activity. Combining silmitasertib with trametinib produced an additive reduction of both resistance-associated pathways with little effect on the viability of normal colon PDOs. The combination also significantly reduced CKII activity, the abundance of active β-catenin and the colorectal cancer stem cell pool.</p><p><strong>Conclusions: </strong>Phosphoproteomic profiling identified CKII as a therapeutic vulnerability in mCRC and provided a rationale for combining silmitasertib with MEK inhibition, offering a candidate combination strategy for mCRC.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13737822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SCGB3A2 marks a low-angiogenesis tumor cell state associated with extracellular PGK2 and angiostatin in lung adenocarcinoma. SCGB3A2在肺腺癌中标志着与细胞外PGK2和血管抑制素相关的低血管生成肿瘤细胞状态。
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-10-30 DOI: 10.1186/s40164-026-00844-7
Shu-Lin Zhao, Yu Cao, Yi-Zuo Shi, Min Zhang, Fu-Qiang Dai, Tian-Hu Wang, Wei Liang, Hong Zhang
{"title":"SCGB3A2 marks a low-angiogenesis tumor cell state associated with extracellular PGK2 and angiostatin in lung adenocarcinoma.","authors":"Shu-Lin Zhao, Yu Cao, Yi-Zuo Shi, Min Zhang, Fu-Qiang Dai, Tian-Hu Wang, Wei Liang, Hong Zhang","doi":"10.1186/s40164-026-00844-7","DOIUrl":"10.1186/s40164-026-00844-7","url":null,"abstract":"<p><p>LUAD exhibits diversity in the mechanisms of angiogenesis and the tumor environment's responses to anti-VEGF therapy, while the tumor-cell-intrinsic mechanisms that prevent vascularization are not well understood. SCGB3A2 (secretoglobin 3A2; HIN-2/UGRP1) is a club/secretory marker of pulmonary adenocarcinoma without established angiogenic function. By using an unsupervised integration approach of two public LUAD single-cell RNA-seq cohorts, we described a SCGB3A2-high malignant epithelial state characterized by an angiogenesis-low phenotype as indicated by the low presence of VEGFA, hypoxic conditions, and a low epithelial-mesenchymal transition (EMT), along with a secretory/anti-inflammatory program, which was confirmed in independent bulk cohorts (TCGA-LUAD, GSE72094) showing that SCGB3A2-high tumors experienced lower instances of angiogenesis, hypoxia, and scores related to EMT/invasion. Using spatial transcriptomics, we positioned SCGB3A2-high tumor cells next to endothelial cells and identified a spatially inferred VEGFA/B-FLT1 interaction pattern. In A549 and NCI-H1975 cells, conditioned medium from SCGB3A2-overexpressing cells contained higher levels of extracellular PGK2-immunoreactive signal and angiostatin and was associated with reduced HUVEC tube formation and VEGFR2 phosphorylation. Thus, SCGB3A2 is a marker for LUAD tumors characterized by low levels of angiogenesis, which is associated with an extracellular PGK2/angiostatin signal.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13723109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HER2 in solid tumors: microenvironment features and multifaceted advances from mechanisms to clinical translation. 实体肿瘤中的HER2:微环境特征和从机制到临床转化的多方面进展
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-10-28 DOI: 10.1186/s40164-026-00850-9
Tianqi Zhang, Cong Tan, Hui Sun, Wenchao Gu, Wenfeng Wang, Midie Xu, Weiqi Sheng
{"title":"HER2 in solid tumors: microenvironment features and multifaceted advances from mechanisms to clinical translation.","authors":"Tianqi Zhang, Cong Tan, Hui Sun, Wenchao Gu, Wenfeng Wang, Midie Xu, Weiqi Sheng","doi":"10.1186/s40164-026-00850-9","DOIUrl":"https://doi.org/10.1186/s40164-026-00850-9","url":null,"abstract":"<p><p>Human epidermal growth factor receptor 2 (HER2) is a well-established oncogenic driver in multiple solid tumors, most prominently in breast and gastric cancers. Beyond gene amplification-driven signaling through canonical PI3K/AKT and RAS/MAPK pathways, emerging evidence reveals that HER2 functions within a highly dynamic and context-dependent tumor ecosystem. Interactions between HER2-positive tumor cells and immune and stromal compartments actively shape the tumor microenvironment, contributing to immune evasion, therapeutic resistance and disease progression. A central challenge in the clinical management of HER2-altered cancers is pronounced spatial and temporal heterogeneity, which undermines both diagnostic accuracy and the durability of targeted therapies. In response, advances in multi-omics profiling, liquid biopsy technologies and artificial intelligence-assisted analytics are redefining HER2 assessment, shifting it from static tissue-based classification towards dynamic, minimally invasive monitoring. In parallel, the therapeutic landscape has evolved from single-agent HER2 blockade to rational combination strategies. In particular, antibody-drug conjugates have emerged as a transformative modality, extending the therapeutic reach of HER2 targeting beyond traditional indications and offering new opportunities to overcome heterogeneity and drug resistance. This review synthesizes current insights into the molecular and microenvironmental biology of HER2-altered solid tumors and discusses how these advances are reshaping next-generation precision oncology.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13718142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation. 胶质母细胞瘤作为一个动态的肿瘤生态系统:从分子改变到治疗翻译。
IF 17.5 1区 医学
Experimental Hematology & Oncology Pub Date : 2026-10-28 DOI: 10.1186/s40164-026-00854-5
Lukas Gorecki
{"title":"Glioblastoma as a dynamic tumor ecosystem: from molecular alterations to therapeutic translation.","authors":"Lukas Gorecki","doi":"10.1186/s40164-026-00854-5","DOIUrl":"https://doi.org/10.1186/s40164-026-00854-5","url":null,"abstract":"<p><p>For more than a century after its initial description, glioblastoma (GBM) has remained one of the most therapeutically refractory human malignancies, resembling an almost impregnable fortress against modern oncology. Despite extensive molecular characterization and identification of numerous actionable targets, survival outcomes have improved only marginally. GBM is characterized by profound spatial and cellular heterogeneity, adaptive signaling rewiring, extensive phenotypic plasticity, an immunosuppressive tumor microenvironment, and major pharmacological constraints imposed by the blood-brain barrier. This review examines the resulting disconnect between biological rationale and clinical outcome through three interrelated translational principles that determine whether mechanistically compelling therapies can achieve meaningful clinical benefit in GBM. First, who is treated and what is biologically active: therapeutic efficacy depends on matching patients to functional pathway dependencies beyond static molecular alterations. Second, whether the drug reaches and modulates its intended target: candidate therapies must achieve sufficient intratumoral exposure and demonstrate target modulation. Third, how the tumor adapts under therapeutic pressure: durable efficacy requires accounting for receptor tyrosine kinase switching, phenotypic plasticity, immune adaptation, and spatial escape. By linking these principles to the molecular, spatial, and pharmacological organization of GBM, this review frames the disease as a dynamic tumor ecosystem and provides a framework for interpreting recurrent clinical failure and guiding more biologically informed therapeutic development.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"15 1","pages":""},"PeriodicalIF":17.5,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13718095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书